Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib | Zendy

Noura J. Choudhury | Zendy; Alex Makhnin | Zendy; Yosef Y. Tobi | Zendy; Robert Michael Daly | Zendy; Isabel R. Preeshagul | Zendy; Afsheen Iqbal | Zendy; Linda S. Ahn | Zendy; Sara A. Hayes | Zendy; Glenn Heller | Zendy; Mark G. Kris | Zendy; Gregory J. Riely | Zendy; Helena A. Yu | Zendy

Open Access

Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

Author(s) -

Noura J. Choudhury,

Alex Makhnin,

Yosef Y. Tobi,

Robert Michael Daly,

Isabel R. Preeshagul,

Afsheen Iqbal,

Linda S. Ahn,

Sara A. Hayes,

Glenn Heller,

Mark G. Kris,

Gregory J. Riely,

Helena A. Yu

Publication year - 2021

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.21.00005

Subject(s) - osimertinib , medicine , epidermal growth factor receptor , oncology , lung cancer , gefitinib , clinical endpoint , progression free survival , t790m , cancer , pharmacology , clinical trial , erlotinib , chemotherapy

Patients with EGFR- mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Preclinical studies suggest that tumors with both EGFR -sensitizing alteration and acquired second-site EGFR resistance alterations after treatment with osimertinib retain sensitivity to second-generation EGFR TKIs. We hypothesized that dacomitinib, a pan-human epidermal growth factor receptor TKI, may be effective in this setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research